### Dasatinib

#### Indication
- Chronic myeloid leukaemia, not elsewhere classified

#### INN
- Dasatinib

#### Medicine type
- Chemical agent

#### List type
- Complementary

#### Additional notes
- Imatinib-resistant chronic myeloid leukaemia

#### Formulations
- Oral > Solid: 20 mg tablet; 50 mg tablet; 70 mg tablet; 80 mg tablet; 100 mg tablet (EML); 140 mg tablet (EML)

#### EML status history
- First added in 2017 (TRS 1006)
- Changed in 2019 (TRS 1021)
- Changed in 2023 (TRS 1049)

#### Sex
- All

#### Age
- Also recommended for children

#### Therapeutic alternatives
- The recommendation is for this specific medicine

#### Patent information
- Main patent is active in several jurisdictions. For more information on specific patents and license status for developing countries visit [www.MedsPal.org](http://www.MedsPal.org)
  - Read more about patents.

#### Summary of evidence and Expert Committee recommendations

Following the review of the age-appropriateness of formulations on the EMLc, the Expert Committee recommended deletion of dasatinib 100 mg and 140 mg tablets from the EMLc.

---

**Tags**
- Cancer
- Dasatinib
- DrugBank